微卫星标记在大熊猫研究中的应用进展

大熊猫是我国保护最为成功、研究最为深入的珍稀动物之一,可以为其它珍稀濒危物种的保护研究工作提供参考。20世纪70年代末期借助无线电颈圈,大熊猫的生态学研究工作取得了突破性进展,近20年来微卫星标记和非损伤性遗传取样技术的联合使用,将大熊猫的保护研究工作提升到一个崭新的高度。本文在综合所有已发表大熊猫微卫星标记的基础上,梳理了微卫星标记在圈养大熊猫亲子鉴定与遗传管理,野生大熊猫个体识别与种群数量调查、遗传多样性评估、扩散和种群遗传结构研究中的应用情况,并着重介绍了其中29个重要的微卫星标记。同时指出目前微卫星标记的使用存在标记选择不统一、等位基因读数无统一规程等问题,并对应用前景进行了前瞻。     

地黄SCoT分子标记体系的建立和指纹图谱的构建

该研究采用L_(25)(5~6)正交设计和单因素两种方法,对影响地黄SCoT-PCR反应的5个因素(模板DNA浓度,引物浓度,ddH_2O和Mix的用量以及退火温度)进行了优化。结果表明:优化后的反应体系总体积为25μL,含有8μL ddH_2O,1μL模板DNA(80 ng·μL~(-1)),1μL引物(8μmol·L~(-1))和15μL Mix,退火温度为45℃。运用30份地黄种质材料,对优化的SCoT-PCR正交体系进行多次重复验证,获得了多态性丰富、条带清晰的扩增图谱,证明该反应体系稳定可靠。利用该体系对32条SCoT引物进行两次筛选,得到14个扩增产物清晰、重复性好且多态性条带相对较高的引物。利用SCoT_4等5条引物构建了上述地黄2个种共30份种质的SCoT指纹图谱。利用这5个SCoT引物指纹图谱可将7个地黄常用栽培品种区分开。这表明SCoT分子标记体系适用于地黄主要品种亲缘关系及遗传多样性的研究,所构建的指纹图谱也为地黄常见的7个栽培品种的区分提供参考依据。     

南盘江流域细叶云南松次生林群落主要木本种群的种间联结

该研究运用方差比率法、χ~2检验、Pearson相关检验和Spearman轶相关检验,对广西雅长兰科植物国家级自然保护区南盘江流域的细叶云南松(Pinus yunnanensis Franch.var.tenuifolia Cheng et Law)次生林14个大树树种(DBH≥10cm)、15个小树树种(5cm≤DBH10cm)和19个幼树树种(1cm≤DBH5cm)进行定量分析,以揭示南盘江流域细叶云南松次生林群落中木本种群的关联性及其更新演替规律,为桂西北细叶云南松林管理保护、干热河谷地区植被恢复和生态重建提供参考依据。结果表明:(1)研究区内细叶云南松林大树和小树的总体关联性表现为不显著负关联,幼树及群落总体表现为不显著正关联;χ~2检验显示,大树和小树负关联种对占多数(分别为48.35%和46.67%),幼树的正关联或负关联种对占比基本持平(分别为40.35%和39.18%),群落整体无关联种对占比较大(41.13%)。(2)Pearson相关系数和Spearman秩相关系数检验显示,细叶云南松林的大树、小树、幼树和群落总体均表现为负关联种对较多,正关联次之。(3)群落大树和小树物种在资源竞争上较激烈,结构不稳定;群落幼树物种适应了林下荫蔽环境,对光照要求较低,种间关系已具有较低的稳定性,个别物种表现出独立性。研究认为,南盘江流域细叶云南松次生林群落物种间存在一定的关联性,但未能形成稳定的配置关系,群落结构尚不稳定,仍处于演替早期阶段。     

人源抗狂犬病病毒单克隆抗体的构建及验证

目的利用人源抗狂犬病病毒ScFv噬菌体抗体库,构建单克隆抗体(单抗)轻、重链质粒,瞬时表达,纯化后验证具有高中和活性的单抗。方法以从ScFv噬菌体抗体库中筛选获得特异性抗体为模板,PCR扩增抗体轻、重链可变区序列,构建人源全分子抗体瞬时转染质粒;轻、重链质粒混合后转染HEK293 EBNA1细胞,瞬时表达全分子抗体。采用Mabselect SuRe介质手动亲和纯化抗体,Nano Vue超微量分光光度计测定蛋白质的质量浓度,快速荧光灶抑制试验(rapid fluorescent focus inhibition test, RFFIT)进行体外中和效价验证。结果成功构建22个轻链质粒,15个重链质粒。通过真核细胞瞬时表达后,经手动亲和纯化后,获得22株单抗。除1株抗体外,其余21株抗体的蛋白质量浓度均>300μg/mL;部分抗体纯度均在90%以上。中和活性结果显示,5株在1 500~1 800 IU/mg之间;8株在800~1 500 IU/mg之间;7株在500~800 IU/mg之间;其余2株在500 IU/mg以下。结论成功构建并验证获得20株中和活性>500 IU/mg的人源抗狂犬病病毒单抗,为单抗混合制剂的研究奠定了基础。     

解脂亚罗酵母菌体外降甘油三酯降胆固醇效果研究

筛选出高效降三酰甘油降胆固醇菌株,为新型药物、食品的制备提供优良菌株。从样品中筛选分离出酵母菌株,并测定菌株降三酰甘油能力,采用磷硫铁比色法测定菌株降胆固醇能力,通过耐酸、耐胆盐及毒性实验研究菌株各项性能,通过生理生化及26S rDNA法对菌株进行鉴定。结果显示,试验筛选出1株高效降脂降胆固醇酵母菌EAM-ZT003T,降三酰甘油能力高达80.2%,菌株具有很好的耐酸、耐胆盐能力,为期42 d的小鼠毒性试验发现,小鼠未出现异常体征,未发现异常死亡,且解剖观察各器官一切正常,菌株经26S rDNA鉴定为解脂亚罗酵母菌(Yarrowia lipolytica)。     

回收乙醇微生物限度检查方法的建立

目的 建立回收乙醇微生物限度检查方法,并对该法的适用性进行确认。方法 探索合适的稀释度来消除乙醇对微生物的抑菌性,寻找合适的过滤量,确定操作步骤。通过多次试验结果确定质量标准。另取3批回收乙醇,进行微生物限度方法适用性试验,分别计算金黄色葡萄球菌( Staphylococcus aureus )、铜绿假单胞菌( Pseudomonas aeruginosa )、枯草芽孢杆菌( Bacillus subtilis )、白色念珠菌( Candida albicans )、黑曲霉( Aspergillus niger )回收率。结果 回收乙醇至少稀释10倍时,可消除其抑菌性。最终确定试验时先用pH 7.0无菌氯化钠-蛋白胨缓冲液将供试品稀释10倍,薄膜过滤法过滤量为每张滤膜100 mL。根据多次微生物限度检查结果,最终确定回收乙醇微生物限度质量标准为不高于10 cfu/mL。方法适用性试验中,3批回收乙醇,5种菌的回收率均在50%~200%范围内,表明该方法适用于回收乙醇的微生物限度检查。结论 回收乙醇经10倍稀释后,可以消除其抑菌性,可以采用薄膜过滤法进行微生物限度检查。     

Risk factors associated with E. coli causing neonatal calf diarrhea

Calf diarrhea is one of the major health challenges in cattle herds. The bacteriological examination of fecal samples collected from apparently healthy and diarrheic calves' revealed isolation of 26 E. coli isolates out of 56 calves with an incidence of 46.4%. Serogroups O1, O26, O44, O55, O115, O119, O125, O146, and O151 were identified from the collected fecal samples. Using PCR all isolates was positive for ompA gene species specific for E. coli. While stx1 and eaeA genes detected with incidence of 3.8 and 19.2% respectively from the isolates. The presence of stx2 gene was negative in the fecal isolates. Among colostrum samples 4 E. coli isolates were detected and serogrouped to O26, O55 and O119. They were negative for eaeA, stx1 and stx2 except strain number 4 (O55) was positive for stx1. E. coli strains were sensitive to norfloxacin (80.7%) and resistant to ampicillin and cefotaxime (100% each). Based on our findings, there was no association between occurrence of E. coli and age of calf (2–14 days), while bottle feeding calf colostrum may be a source of E. coli contamination.     

A flexible summary statistics-based colocalization method with application to the mucin cystic fibrosis lung disease modifier locus

Mucus obstruction is a central feature in the cystic fibrosis (CF) airways. A genome-wide association study (GWAS) of lung disease by the CF Gene Modifier Consortium (CFGMC) identified a significant locus containing two mucin genes, MUC20 and MUC4. Expression quantitative trait locus (eQTL) analysis using human nasal epithelia (HNE) from 94 CF-affected Canadians in the CFGMC demonstrated MUC4 eQTLs that mirrored the lung association pattern in the region, suggesting that MUC4 expression may mediate CF lung disease. Complications arose, however, with colocalization testing using existing methods: the locus is complex and the associated SNPs span a 0.2 Mb region with high linkage disequilibrium (LD) and evidence of allelic heterogeneity. We previously developed the Simple Sum (SS), a powerful colocalization test in regions with allelic heterogeneity, but SS assumed eQTLs to be present to achieve type I error control. Here we propose a two-stage SS (SS2) colocalization test that avoids a priori eQTL assumptions, accounts for multiple hypothesis testing and the composite null hypothesis, and enables meta-analysis. We compare SS2 to published approaches through simulation and demonstrate type I error control for all settings with the greatest power in the presence of high LD and allelic heterogeneity. Applying SS2 to the MUC20/MUC4 CF lung disease locus with eQTLs from CF HNE revealed significant colocalization with MUC4 (p = 1.31 × 10^?5) rather than with MUC20. The SS2 is a powerful method to inform the responsible gene(s) at a locus and guide future functional studies. SS2 has been implemented in the application LocusFocus.     

探索以“霍乱弧菌检测虚拟仿真实验”为载体的混合式实验教学模式

虚拟仿真实验是一种现代信息化和智慧教学的重要方法,对高等医学院校教学质量的发展起到重要的推进作用。我们自主开发建设的“霍乱弧菌检测与防控虚拟仿真实验”,既弥补了因生物安全问题不能开展的实验教学,也解决了微生物学检验实验教学中存在的操作标准化问题。采用“三步进阶”混合教学模式,实现以“学生为中心”的师生互动模式,创建“设计性实验报告”,与育人元素有机结合,培育医学生的职业使命感。细化考核标准,实现过程性评价。探索课前启发铺垫、课中内化升华、课后巩固拓展混合式实验教学模式,有效提高学生的实验技能,实现知行合一、素能共育的教学目标。     

Changes in prostate cancer incidence,mortality and survival in relation to prostate specific antigen testing in New South Wales,Australia

BackgroundTo examine changes in prostate cancer incidence and mortality rates, and 5-year relative survival, in relation to changes in the rate of prostate specific antigen (PSA) screening tests and the use of radical prostatectomy (RP) in the Australian population.MethodsProstate cancer stage-specific incidence rates, 5-year relative survival and mortality rates were estimated using New South Wales Cancer Registry data. PSA screening test rates and RP/Incidence ratios were estimated from Medicare Benefits Schedule claims data. We used multiple imputation to impute stage for cases with “unknown” stage at diagnosis. Annual percentage changes (APC) in rates were estimated using Joinpoint regression.ResultsTrends in the age-standardized incidence rates for localized disease largely mirrored the trends in PSA screening test rates, with a substantial ‘spike’ in the rates occurring in 1994, followed by a second ‘spike’ in 2008, and then a significant decrease from 2008 to 2015 (APC −6.7, 95% CI −8.2, −5.1). Increasing trends in incidence rates were observed for regional stage from the early 2000s, while decreasing or stable trends were observed for distant stage since 1993. The overall RP/Incidence ratio increased from 1998 to 2003 (APC 9.6, 95% CI 3.8, 15.6), then remained relatively stable to 2015. The overall 5-year relative survival for prostate cancer increased from 58.4% (95% CI: 55.0–61.7%) in 1981–1985 to 91.3% (95% CI: 90.5–92.1%) in 2011–2015. Prostate cancer mortality rates decreased from 1990 onwards (1990–2006: APC −1.7, 95% CI −2.1, −1.2; 2006–2017: APC −3.8, 95% CI −4.4, −3.1).ConclusionsOverall, there was a decrease in the incidence rate of localized prostate cancer after 2008, an increase in survival over time and a decrease in the mortality rate since the 1990s. This seems to indicate that the more conservative use of PSA screening tests in clinical practice since 2008 has not had a negative impact on population-wide prostate cancer outcomes.